Please Wait.....
Report
Pet Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Therapy (Surgery, Radiotherapy, Chemotherapy, Immunotherapy, Others), By Animal Type (Canine, Feline, Others), By Cancer Type (Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer, Others), By Company, and By Region
Market Report I 2022-11-01 I 114 Pages I TechSci Research
The global pet cancer therapeutics market is anticipated to observe an impressive growth during the forecast period, 2023-2027. The major factors include growing consciousness of pet's health and increasing incidences of cancer among animals. Cancer in pets is one of the primary reasons for death, globally. Nowadays, pets have better chances to get diagnosed with cancer due which early adoption of treatment plans are required, which bolster the growth of the market. The other factors supporting the market's growth are rise in pet ownership or animal adoption, advancement in diagnostic techniques and rise in R&D initiatives. Additionally, heavy investments in research and development activities coupled with oncology treatment and management in pets offers lucrative opportunities to the market players in upcoming years.
Increasing Awareness regarding Pet Healthcare and Treatments
The increasing domestication of animals and growing concerns regarding pet health among the people are supporting the market growth. In 2021, number of pet dogs owned worldwide was 471 million. People are becoming more thoughtful about their pet's health and are expending generously on the best available animal therapeutics. Average American yearly spending on pet dogs is estimated to be USD 1201. In addition, growing pet's health awareness programs is augmenting the growth of the market. For instance, the Blue Buffalo Foundation and the Pet Cancer Awareness Program (PCA) are some initiatives which raise awareness and provide information to the pet parents.
Increasing Prevalence of Cancer
The growing prevalence of cancer among pet animals, is a contributing factor for the growth of the market. Cancer is one of the key causes of death in pets, mostly in dogs that are older than 10 years. According to the Veterinary Cancer Society, in 2017, cancer was the foremost cause of death in 47% of dogs, especially those that are over the age of 10, and 32% of cats. Leukemia and lymphoma are very common cancer in cats and certain breeds of elderly dogs. In 2017, Animal Cancer Foundation published a study, which revealed approximately around 25% of all dogs will develop a tumor at some point in their life.
Technological Advancements
Various technological advancements, such as the development of highly targeted and specific cures for animal cancer treatment with minimal side effects, are also supporting the market growth. Increasing R&D initiatives for cancer management is propelling the market growth, as various anti-cancer therapies are launching for veterinary cancer treatment. For instance, in 2017, Jackson Laboratory launched Tallwood Canine Cancer Research Initiative (TCCRI), to generate a biobank of dog tumors for giving insights on cancer cure through research. Also, organizations such as Animal Cancer Foundation, Veterinary Cancer Society, Petco Foundation and PetCure Oncology are doing oncology research such as canine cancer genome project to gain the knowledge related to the genetic makeup of cancer tumors in animals. The foremost focus is on the development of anticancer drugs and improvising their effectiveness and reducing their toxic effects on the pet's body.
Market Segmentation
The global pet cancer therapeutics market is segmented into therapy, animal type, cancer type, and company. Based on therapy, the market is divided into surgery, radiotherapy, chemotherapy, immunotherapy, and others. Based on animal type, the market is divided into canine, feline, and others. Based on cancer type, the market is segmented into lymphoma, mast cell cancer, mammary & squamous cell cancer, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising domestication and rise in the occurrence of pet cancers in the country.
Market Players
C.H. Boehringer Sohn Ko. KG, ELIAS Animal Health, LLC, Zoetis Inc., AB Science S.A., Karyopharm Therapeutics, Inc., Vivesto AB, Merial Inc., Elanco Animal Health, Inc., Dechra Pharmaceuticals PLC (Anivive Lifesciences), and Torigen Pharmaceuticals Inc. are some of the leading companies operating in the market.
Report Scope:
In this report, global pet cancer therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
- Pet Cancer Therapeutics Market, By Therapy:
o Surgery
o Radiotherapy
o Chemotherapy
o Immunotherapy
o Others
- Pet Cancer Therapeutics Market, By Animal Type:
o Canine
o Feline
o Others
- Pet Cancer Therapeutics Market, By Cancer Type:
o Lymphoma
o Mast Cell Cancer
o Mammary & Squamous Cell Cancer
o Others
- Pet Cancer Therapeutics Market, By Region:
o North America
- United States
- Canada
- Mexico
o Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
o Europe & CIS
- Germany
- France
- United Kingdom
- Spain
- Italy
o South America
- Brazil
- Argentina
- Colombia
o Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in Pet Cancer Therapeutics Market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. Product Overview
2. Research Methodology
3. Executive Summary
4. Impact of COVID-19 on Global Pet Cancer Therapeutics Market
5. Voice of Customer
6. Global Pet Cancer Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapy (Surgery, Radiotherapy, Chemotherapy, Immunotherapy, Others)
6.2.2. By Animal Type (Canine, Feline, Others)
6.2.3. By Cancer Type (Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer, Others)
6.2.4. By Company (2021)
6.2.5. By Region
6.3. Market Map
7. North America Pet Cancer Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapy
7.2.2. By Animal Type
7.2.3. By Cancer Type
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Pet Cancer Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Therapy
7.3.1.2.2. By Animal Type
7.3.1.2.3. By Cancer Type
7.3.2. Mexico Pet Cancer Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Therapy
7.3.2.2.2. By Animal Type
7.3.2.2.3. By Cancer Type
7.3.3. Canada Pet Cancer Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Therapy
7.3.3.2.2. By Animal Type
7.3.3.2.3. By Cancer Type
8. Europe Pet Cancer Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapy
8.2.2. By Animal Type
8.2.3. By Cancer Type
8.2.4. By Country
8.3. Europe: Country Analysis
8.3.1. France Pet Cancer Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapy
8.3.1.2.2. By Animal Type
8.3.1.2.3. By Cancer Type
8.3.2. Germany Pet Cancer Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapy
8.3.2.2.2. By Animal Type
8.3.2.2.3. By Cancer Type
8.3.3. United Kingdom Pet Cancer Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapy
8.3.3.2.2. By Animal Type
8.3.3.2.3. By Cancer Type
8.3.4. Italy Pet Cancer Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Therapy
8.3.4.2.2. By Animal Type
8.3.4.2.3. By Cancer Type
8.3.5. Spain Pet Cancer Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Therapy
8.3.5.2.2. By Animal Type
8.3.5.2.3. By Cancer Type
9. Asia-Pacific Pet Cancer Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapy
9.2.2. By Animal Type
9.2.3. By Cancer Type
9.2.4. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Pet Cancer Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapy
9.3.1.2.2. By Animal Type
9.3.1.2.3. By Cancer Type
9.3.2. India Pet Cancer Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapy
9.3.2.2.2. By Animal Type
9.3.2.2.3. By Cancer Type
9.3.3. Japan Pet Cancer Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapy
9.3.3.2.2. By Animal Type
9.3.3.2.3. By Cancer Type
9.3.4. South Korea Pet Cancer Therapeutics Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Therapy
9.3.4.2.2. By Animal Type
9.3.4.2.3. By Cancer Type
9.3.5. Australia Pet Cancer Therapeutics Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Therapy
9.3.5.2.2. By Animal Type
9.3.5.2.3. By Cancer Type
10. South America Pet Cancer Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapy
10.2.2. By Animal Type
10.2.3. By Cancer Type
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Pet Cancer Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Therapy
10.3.1.2.2. By Animal Type
10.3.1.2.3. By Cancer Type
10.3.2. Argentina Pet Cancer Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Therapy
10.3.2.2.2. By Animal Type
10.3.2.2.3. By Cancer Type
10.3.3. Colombia Pet Cancer Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Therapy
10.3.3.2.2. By Animal Type
10.3.3.2.3. By Cancer Type
11. Middle East and Africa Pet Cancer Therapeutics Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Therapy
11.2.2. By Animal Type
11.2.3. By Cancer Type
11.2.4. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Pet Cancer Therapeutics Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Therapy
11.3.1.2.2. By Animal Type
11.3.1.2.3. By Cancer Type
11.3.2. Saudi Arabia Pet Cancer Therapeutics Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Therapy
11.3.2.2.2. By Animal Type
11.3.2.2.3. By Cancer Type
11.3.3. UAE Pet Cancer Therapeutics Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Therapy
11.3.3.2.2. By Animal Type
11.3.3.2.3. By Cancer Type
11.3.4. Egypt Pet Cancer Therapeutics Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Therapy
11.3.4.2.2. By Animal Type
11.3.4.2.3. By Cancer Type
11.3.5. Turkey Pet Cancer Therapeutics Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1. By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1. By Therapy
11.3.5.2.2. By Animal Type
11.3.5.2.3. By Cancer Type
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
14. Competitive Landscape
14.1. C.H. Boehringer Sohn Ko. KG
14.2. ELIAS Animal Health, LLC
14.3. Zoetis Inc.
14.4. AB Science S.A.
14.5. Karyopharm Therapeutics, Inc.
14.6. Vivesto AB
14.7. Merial Inc.
14.8. Elanco Animal Health, Inc.
14.9. Dechra Pharmaceuticals PLC (Anivive Lifesciences)
14.10. Torigen Pharmaceuticals Inc.
15. Strategic Recommendations
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security